The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the incidence and risk factors for infections in the real-world setting for patients with newly diagnosed multiple myeloma (NDMM) treated with modern induction regimens. Prof. Kastritis highlights several risk factors associated with severe infections, and notes that modern regimens did not seem to increase the risk of severe infections in the short term. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
